UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Cystathionine γ-lyase deficiency mediates neurodegeneration in Huntington’s disease

Nature (London), 2014-05, Vol.509 (7498), p.96-100

2014

Volltextzugriff (PDF)

Potential therapeutic uses of BDNF in neurological and psychiatric disorders

Nature reviews. Drug discovery, 2011-03, Vol.10 (3), p.209-219

2011

Volltextzugriff (PDF)

Small molecule splicing modifiers with systemic HTT-lowering activity

Nature communications, 2021-12, Vol.12 (1), p.7299-7299, Article 7299

2021

Volltextzugriff (PDF)

An orally available, brain penetrant, small molecule lowers huntingtin levels by enhancing pseudoexon inclusion

Nature communications, 2022-03, Vol.13 (1), p.1150-1150, Article 1150

2022

Volltextzugriff (PDF)

Parthenolide ameliorates 3-nitropropionic acid-induced Huntington's disease-like aberrations via modulating NLRP3 inflammasome, reducing microglial activation and inducing astrocyte shifting

Molecular medicine (Cambridge, Mass.), 2024-09, Vol.30 (1), p.158-21, Article 158

2024

Volltextzugriff (PDF)

Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease

Nature genetics, 2004-06, Vol.36 (6), p.585-595

2004

Volltextzugriff (PDF)

Proteostasis in Huntington's disease: disease mechanisms and therapeutic opportunities

Acta pharmacologica Sinica, 2018-05, Vol.39 (5), p.754-769

2018

Volltextzugriff (PDF)

Combined Treatment with the Mood Stabilizers Lithium and Valproate Produces Multiple Beneficial Effects in Transgenic Mouse Models of Huntington's Disease

Neuropsychopharmacology (New York, N.Y.), 2011-11, Vol.36 (12), p.2406-2421

2011

Volltextzugriff (PDF)

Convergent pathogenic pathways in Alzheimer's and Huntington's diseases: shared targets for drug development

Nature reviews. Drug discovery, 2011-11, Vol.10 (11), p.853-867

2011

Volltextzugriff (PDF)

Gossypol, a novel modulator of VCP, induces autophagic degradation of mutant huntingtin by promoting the formation of VCP/p97-LC3-mHTT complex

Acta pharmacologica Sinica, 2021-10, Vol.42 (10), p.1556-1566

2021

Volltextzugriff (PDF)

Dantrolene is neuroprotective in Huntington's disease transgenic mouse model

Molecular neurodegeneration, 2011-11, Vol.6 (1), p.81-81, Article 81

2011

Volltextzugriff (PDF)

Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease

Nature medicine, 2004-02, Vol.10 (2), p.148-154

2004

Volltextzugriff (PDF)

Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease

Nature medicine, 2000-07, Vol.6 (7), p.797-801

2000

Volltextzugriff (PDF)

Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease

Nature (London), 1999-05, Vol.399 (6733), p.263-267

1999

Volltextzugriff (PDF)

Latrepirdine: molecular mechanisms underlying potential therapeutic roles in Alzheimer’s and other neurodegenerative diseases

Translational psychiatry, 2013-12, Vol.3 (12), p.e332-e332

2013

Volltextzugriff (PDF)

Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine

Nature medicine, 2002-02, Vol.8 (2), p.143-149

2002

Volltextzugriff (PDF)

Systemic delivery of P42 peptide: a new weapon to fight Huntington's disease

Acta neuropathologica communications, 2014-08, Vol.2 (1), p.86, Article 86

2014

Volltextzugriff (PDF)

Treating Mouse Models of Huntington Disease

Neuropsychopharmacology (New York, N.Y.), 2011-11, Vol.36 (12), p.2373-2374

2011

Volltextzugriff (PDF)

Getting a handle on Huntington's disease: silencing neurodegeneration

Nature medicine, 2009-03, Vol.15 (3), p.252-253

La Spada, Albert R

2009

Volltextzugriff (PDF)

Tricyclic pyrone compounds prevent aggregation and reverse cellular phenotypes caused by expression of mutant huntingtin protein in striatal neurons

BMC neuroscience, 2009-07, Vol.10 (1), p.73-73, Article 73

2009

Volltextzugriff (PDF)

Therapeutic opportunities in polyglutamine disease

Nature medicine, 2001-04, Vol.7 (4), p.419-423

2001

Volltextzugriff (PDF)

Short G-rich oligonucleotides as a potential therapeutic for Huntington's Disease

BMC neuroscience, 2006-10, Vol.7 (1), p.65-65, Article 65

2006

Volltextzugriff (PDF)

Development of novel therapies for Huntington's disease: hope and challenge

Acta pharmacologica Sinica, 2005-02, Vol.26 (2), p.129-142

2005

Volltextzugriff (PDF)

Sweet relief for Huntington disease

Nature medicine, 2004-02, Vol.10 (2), p.123-124

2004

Volltextzugriff (PDF)

1 – 25 von 38

Suche als RSS-Feed

Aktive Filter

SprachePortugiesisch

KollektionNexis Uni

ThemaAnimals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(37)
Mit Volltextzugriff
(32)

Publikationsform

Artikel
(37)
Newsletter-Artikel
(1)

Sprache

Englisch
(38)

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

A slipped-CAG DNA-binding small molecule induces trinucleotide-repeat contractions in vivo

Cystathionine γ-lyase deficiency mediates neurodegeneration in Huntington’s disease

Potential therapeutic uses of BDNF in neurological and psychiatric disorders

Small molecule splicing modifiers with systemic HTT-lowering activity

An orally available, brain penetrant, small molecule lowers huntingtin levels by enhancing pseudoexon inclusion

Parthenolide ameliorates 3-nitropropionic acid-induced Huntington's disease-like aberrations via modulating NLRP3 inflammasome, reducing microglial activation and inducing astrocyte shifting

Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease

Proteostasis in Huntington's disease: disease mechanisms and therapeutic opportunities

Combined Treatment with the Mood Stabilizers Lithium and Valproate Produces Multiple Beneficial Effects in Transgenic Mouse Models of Huntington's Disease

Convergent pathogenic pathways in Alzheimer's and Huntington's diseases: shared targets for drug development

Gossypol, a novel modulator of VCP, induces autophagic degradation of mutant huntingtin by promoting the formation of VCP/p97-LC3-mHTT complex

Dantrolene is neuroprotective in Huntington's disease transgenic mouse model

Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease

Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease

Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease

Latrepirdine: molecular mechanisms underlying potential therapeutic roles in Alzheimer’s and other neurodegenerative diseases

Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine

Systemic delivery of P42 peptide: a new weapon to fight Huntington's disease

Treating Mouse Models of Huntington Disease

Getting a handle on Huntington's disease: silencing neurodegeneration

Tricyclic pyrone compounds prevent aggregation and reverse cellular phenotypes caused by expression of mutant huntingtin protein in striatal neurons

Therapeutic opportunities in polyglutamine disease

Short G-rich oligonucleotides as a potential therapeutic for Huntington's Disease

Development of novel therapies for Huntington's disease: hope and challenge

Sweet relief for Huntington disease

Aktive Filter

Suchergebnisse filtern